NorthWest Biotherapeutics Inc (NWBO)

[anders2211]

she is referring to this article:

https://www.pharmaceutical-technology.com/comment/northwest-bios-dcvax-l-hype-warranted-glioblastoma-patients/

KOLs noted that Northwest Bio’s data was presented in an unusual way for a randomised Phase III trial and the criteria for selection was highly meticulous with an estimated 1,599 patients screened and 1,268 of these patients excluded from the trial. It is speculated that only the patients expected to live longer were included in the study due to the scrupulous selection criteria, which could have led to bias in the dataset.

for anyone new here:
1 in 4 were because they were found to not have a GBM The 331 patients treated have similar characteristics to other recent GBM trials.

90% got DCVax and they did exclude those who progressed prior to the end of radiotherapy, before the start of this treatment, as most trials do. The fact screening was so early is at least part of the reason they have a lot of exclusions.

There was no biased excluding. The trial has been set up in such a way as a brain physician would detect early GBM and start treating with DCVAX as other trials have done.